• 1
    Last JM. A Dictionary of Epidemiology, 3rd edn. New York: Oxford University Press, 1995.
  • 2
    National Diabetes Data Group. Classification and diagnosis of diabetes and other categories of glucose intolerance. Diabetes 1979; 28: 10391057.
  • 3
    WHO Expert Committee on Diabetes Mellitus. Technical Report Series 646, Second report. Geneva: World Health Organisation, 1980.
  • 4
    WHO Study Group. Diabetes Mellitus. Technical report Series 727. Geneva: World Health Organisation, 1985.
  • 5
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 11831197.
  • 6
    World Health Organisation. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organisation, 1999.
  • 7
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281303.
  • 8
    Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48: 21972203.
  • 9
    Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000; 17: 433440.
  • 10
    Dunstan D, Zimmet P, Welborn T, De Courten M, Cameron A, Sicree R et al. The rising prevalence of diabetes mellitus and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 2002; 25: 829834.
  • 11
    Shaw J, Zimmet P, De Courten M, Dowse G, Chitson P, Gareeboo H et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999; 22: 399402.
  • 12
    Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000; 23: 11131118.
  • 13
    Larsson H, Berglund G, Lindgarde F, Ahren B. Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia 1998; 41: 11241125.
  • 14
    De Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998; 21: 16861690.
  • 15
    Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980–85 World Health Organization diagnostic criteria. Diabetes Care 1997; 20: 18591862.
  • 16
    Ko GT, Chan JC, Woo J, Cockram CS. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care 1998; 21: 20942097.
  • 17
    The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617621.
  • 18
    DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br Med J 1998; 317: 371375.
  • 19
    Qiau Q, Hu G, Tuomilehto J, Balkau B, Bord-Johnsen K, for the DECODE Study Group. Age and sex specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts. 37th Annual meeting of the European Diabetes Epidemiology Group, Oxford 2002. Abstract 37.
  • 20
    Qiao QNT, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N. Comparison of the fasting and the 2-hour glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000; 43: 2000.
  • 21
    DECODA Study Group. Age and sex specific prevalence of diabetes and impaired glucose regulation in 10 Asian cohorts. Diabetes Research & Clinical Practice 2002; 56(1): 540.
  • 22
    Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233240.
  • 23
    Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 11081112.
  • 24
    Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 1999; 22: 14901493.
  • 25
    Wareham N, Byrne C, Williams D, Day N, Hales C. Fasting proinsulin concentrations predict the development of Type 2 diabetes. Diabetes Care 1999; 22: 262270.
  • 26
    Gimeno SG, Ferreira SR, Franco LJ, Iunes M. Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. The Japanese-Brazilian Diabetes Study Group. Diabetes Care 1998; 21: 18891892.
  • 27
    Eschwege E, Charles MA, Simon D, Thibult N, Balkau B, Paris Prospective S. Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. Diabetes Care 2001; 24: 19411944.
  • 28
    Rathmann W, Giani G, Mielck A. Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria. Diabetologia 1999; 42: 12681269.
  • 29
    Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212218.
  • 30
    Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study. Diabet Med 2000; 16: 212218.
  • 31
    Decode Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397405.
  • 32
    Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 3238.
  • 33
    De Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926931.
  • 34
    Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 1518.
  • 35
    Stern MP. Diabetes and cardiovascular disease. The ‘common soil’ hypothesis. Diabetes 1995; 44: 369374.
  • 36
    Tuomilehto J. Primary prevention of non-communicable diseases. In: HitmanG, ed. Type 2 Diabetes. Prediction and Prevention. Chichester: John Wiley & Sons, 1999; 213238.
  • 37
    Thompson WG. Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. Mayo Clinic Proc 2001; 76: 11371143.
  • 38
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145153.
  • 39
    Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357362.
  • 40
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393403.
  • 41
    Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920926.
  • 42
    Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 6171.
  • 43
    Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 28932898.
  • 44
    Williams K, Davey J, Haffner S, Stern MDSA. Logistic regression model predicting the incidence of either diabetes or cardiovascular disease in the San Antonio Heart Study: a score sheet for risk assessment. Diabetes 2001; 50: A204.
  • 45
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 13431350.
  • 46
    Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M. et al. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomised clinical trial. The STOP-NIDDM randomised Trial. Lancet 2002; 359: 20722077.
  • 47
    Chiasson J, Gomis R, Hanefeld M, Josse R, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998; 21: 17201725.
  • 48
    Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT Diabetes Study. Diabetes Care 1997; 20: 537544.
  • 49
    Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305313.
  • 50
    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (Troglitazone In the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Controlled Clin Trials 1998; 19: 217231.
  • 51
    Buchanan T, Xiang A, Peters R, Kjos S, Marroquin A, Goico J et al. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 2001; 50 (Suppl. 2): A81.
  • 52
    Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocrine J 2000; 47: 639641.
  • 53
    Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Sys Pharm 2000; 57: 12311241.
  • 54
    Hunt K, Williams K, Haffner S, Stern M. Predicting impaired glucose tolerance (IGT) among individuals with a non-diabetic fasting glucose value. The San Anotnio Heart Study. Diabetes 2002; 51: A229.
  • 55
    Ruige JB, De Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997; 20: 491496.
  • 56
    Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ et al. Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999; 22: 213219.
  • 57
    Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. In: 20th International Symposium on Diabetes and Nutrition, European Association for the Study of Diabetes; June 27–30 2002; Samos, Greece; 2002.
  • 58
    Motala AA, Omar MAK, Gouws E. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care 1997; 20: 11011107.
  • 59
    Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. Transient impaired glucose tolerance in Pima Indians: is it important? BMJ 1988; 297: 14381441.